Australia markets closed

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.5000+0.5800 (+14.80%)
At close: 04:00PM EDT
4.3500 -0.15 (-3.33%)
Pre-market: 04:09AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 404.86M
Enterprise value 414.30M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.45
Price/book (mrq)N/A
Enterprise value/revenue 8.19
Enterprise value/EBITDA 350.51

Trading information

Stock price history

Beta (5Y monthly) 2.91
52-week change 3223.74%
S&P500 52-week change 321.23%
52-week high 36.2300
52-week low 31.1500
50-day moving average 33.9680
200-day moving average 32.3922

Share statistics

Avg vol (3-month) 32.45M
Avg vol (10-day) 32.43M
Shares outstanding 589.97M
Implied shares outstanding 689.97M
Float 865.02M
% held by insiders 15.03%
% held by institutions 134.33%
Shares short (28 Mar 2024) 42.27M
Short ratio (28 Mar 2024) 40.56
Short % of float (28 Mar 2024) 43.03%
Short % of shares outstanding (28 Mar 2024) 42.53%
Shares short (prior month 29 Feb 2024) 41.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -15.56%
Operating margin (ttm)-29.61%

Management effectiveness

Return on assets (ttm)-16.49%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)50.58M
Revenue per share (ttm)0.83
Quarterly revenue growth (yoy)23.60%
Gross profit (ttm)N/A
EBITDA -13.73M
Net income avi to common (ttm)-7.87M
Diluted EPS (ttm)-0.1300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)23.87M
Total cash per share (mrq)0.33
Total debt (mrq)33.32M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.24
Book value per share (mrq)-1.55

Cash flow statement

Operating cash flow (ttm)-6.38M
Levered free cash flow (ttm)-16.22M